Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | ROIV |
---|---|---|
09:32 ET | 108363 | 12.22 |
09:34 ET | 24981 | 12.18 |
09:36 ET | 21410 | 12.25 |
09:38 ET | 23381 | 12.28 |
09:39 ET | 20133 | 12.3 |
09:41 ET | 14659 | 12.26 |
09:43 ET | 80407 | 12.355 |
09:45 ET | 24516 | 12.315 |
09:48 ET | 21843 | 12.305 |
09:50 ET | 32403 | 12.265 |
09:52 ET | 19543 | 12.22 |
09:54 ET | 28775 | 12.235 |
09:56 ET | 40256 | 12.26 |
09:57 ET | 15487 | 12.215 |
09:59 ET | 28786 | 12.235 |
10:01 ET | 33435 | 12.21 |
10:03 ET | 23227 | 12.185 |
10:06 ET | 160911 | 12.045 |
10:08 ET | 96943 | 12.105 |
10:10 ET | 65180 | 12.095 |
10:12 ET | 15819 | 12.1 |
10:14 ET | 20129 | 12.08 |
10:15 ET | 12935 | 12.045 |
10:17 ET | 25703 | 12.045 |
10:19 ET | 68831 | 12.075 |
10:21 ET | 13903 | 12.095 |
10:24 ET | 11027 | 12.105 |
10:26 ET | 44155 | 12.095 |
10:28 ET | 20745 | 12.1 |
10:30 ET | 18630 | 12.14 |
10:32 ET | 77645 | 12.13 |
10:33 ET | 23717 | 12.175 |
10:35 ET | 11469 | 12.18 |
10:37 ET | 29590 | 12.165 |
10:39 ET | 21239 | 12.175 |
10:42 ET | 6584 | 12.17 |
10:44 ET | 7727 | 12.175 |
10:46 ET | 25353 | 12.19 |
10:48 ET | 11474 | 12.175 |
10:50 ET | 11242 | 12.19 |
10:51 ET | 8395 | 12.185 |
10:53 ET | 10172 | 12.165 |
10:55 ET | 10902 | 12.18 |
10:57 ET | 12625 | 12.175 |
11:00 ET | 10726 | 12.185 |
11:02 ET | 11513 | 12.195 |
11:04 ET | 17695 | 12.205 |
11:06 ET | 41390 | 12.215 |
11:08 ET | 16679 | 12.205 |
11:09 ET | 37717 | 12.2 |
11:11 ET | 3807 | 12.205 |
11:13 ET | 21338 | 12.195 |
11:15 ET | 2159 | 12.19 |
11:18 ET | 47343 | 12.225 |
11:20 ET | 5146 | 12.22 |
11:22 ET | 15649 | 12.225 |
11:24 ET | 10575 | 12.215 |
11:26 ET | 2738 | 12.215 |
11:27 ET | 26436 | 12.21 |
11:29 ET | 37144 | 12.23 |
11:31 ET | 20851 | 12.225 |
11:33 ET | 12492 | 12.235 |
11:36 ET | 7127 | 12.235 |
11:38 ET | 3652 | 12.23 |
11:40 ET | 48390 | 12.235 |
11:42 ET | 14131 | 12.22 |
11:44 ET | 45447 | 12.225 |
11:45 ET | 13128 | 12.225 |
11:47 ET | 16307 | 12.205 |
11:49 ET | 32435 | 12.15 |
11:51 ET | 34671 | 12.175 |
11:54 ET | 5014 | 12.175 |
11:56 ET | 7453 | 12.175 |
11:58 ET | 8015 | 12.18 |
12:00 ET | 19589 | 12.145 |
12:02 ET | 19560 | 12.13 |
12:03 ET | 4371 | 12.135 |
12:05 ET | 13062 | 12.125 |
12:07 ET | 16364 | 12.125 |
12:09 ET | 11467 | 12.145 |
12:12 ET | 12420 | 12.16 |
12:14 ET | 12015 | 12.155 |
12:16 ET | 2430 | 12.16 |
12:18 ET | 7570 | 12.17 |
12:20 ET | 21648 | 12.16 |
12:21 ET | 4711 | 12.155 |
12:23 ET | 38833 | 12.135 |
12:25 ET | 16684 | 12.13 |
12:27 ET | 25071 | 12.145 |
12:30 ET | 4446 | 12.145 |
12:32 ET | 11369 | 12.16 |
12:34 ET | 14623 | 12.115 |
12:36 ET | 3964 | 12.115 |
12:38 ET | 16288 | 12.15 |
12:39 ET | 8044 | 12.145 |
12:41 ET | 18974 | 12.145 |
12:43 ET | 7324 | 12.135 |
12:45 ET | 7494 | 12.13 |
12:48 ET | 3352 | 12.13 |
12:50 ET | 10863 | 12.13 |
12:52 ET | 9384 | 12.13 |
12:54 ET | 2400 | 12.13 |
12:56 ET | 5113 | 12.14 |
12:57 ET | 76769 | 12.18 |
12:59 ET | 18922 | 12.1509 |
01:01 ET | 13844 | 12.125 |
01:03 ET | 33958 | 12.11 |
01:06 ET | 20624 | 12.095 |
01:08 ET | 16465 | 12.085 |
01:10 ET | 1516 | 12.084 |
01:12 ET | 6118 | 12.085 |
01:14 ET | 17089 | 12.06 |
01:15 ET | 3463 | 12.055 |
01:17 ET | 4997 | 12.055 |
01:19 ET | 13434 | 12.075 |
01:21 ET | 15385 | 12.055 |
01:24 ET | 1204 | 12.055 |
01:26 ET | 10333 | 12.065 |
01:28 ET | 12174 | 12.075 |
01:30 ET | 3840 | 12.08 |
01:32 ET | 2240 | 12.08 |
01:33 ET | 18973 | 12.075 |
01:35 ET | 5715 | 12.065 |
01:37 ET | 18242 | 12.07 |
01:39 ET | 18980 | 12.065 |
01:42 ET | 1941 | 12.07 |
01:44 ET | 8155 | 12.055 |
01:46 ET | 7514 | 12.045 |
01:48 ET | 7659 | 12.06 |
01:50 ET | 7731 | 12.06 |
01:51 ET | 32651 | 12.035 |
01:53 ET | 24291 | 12.055 |
01:55 ET | 12295 | 12.055 |
01:57 ET | 7491 | 12.06 |
02:00 ET | 27254 | 12.04 |
02:02 ET | 80317 | 12.2047 |
02:04 ET | 126024 | 12.13 |
02:06 ET | 66948 | 12.14 |
02:08 ET | 72020 | 12.0995 |
02:09 ET | 86183 | 12.085 |
02:11 ET | 97465 | 12.11 |
02:13 ET | 42237 | 12.075 |
02:15 ET | 63350 | 12.06 |
02:18 ET | 23507 | 12.065 |
02:20 ET | 24810 | 12.08 |
02:22 ET | 15538 | 12.09 |
02:24 ET | 24662 | 12.095 |
02:26 ET | 16426 | 12.085 |
02:27 ET | 42627 | 12.125 |
02:29 ET | 62036 | 12.14 |
02:31 ET | 20020 | 12.185 |
02:33 ET | 120168 | 12.2 |
02:36 ET | 65360 | 12.19 |
02:38 ET | 53996 | 12.14 |
02:40 ET | 25198 | 12.175 |
02:42 ET | 25455 | 12.16 |
02:44 ET | 27431 | 12.14 |
02:45 ET | 74433 | 12.07 |
02:47 ET | 67962 | 12.115 |
02:49 ET | 27235 | 12.1 |
02:51 ET | 25794 | 12.1209 |
02:54 ET | 23784 | 12.15 |
02:56 ET | 26699 | 12.14 |
02:58 ET | 33547 | 12.13 |
03:00 ET | 17662 | 12.1 |
03:02 ET | 23850 | 12.09 |
03:03 ET | 48397 | 12.065 |
03:05 ET | 37773 | 12.075 |
03:07 ET | 36983 | 12.02 |
03:09 ET | 21448 | 12 |
03:12 ET | 58956 | 12.005 |
03:14 ET | 29312 | 12.03 |
03:16 ET | 8346 | 12.05 |
03:18 ET | 21521 | 12.04 |
03:20 ET | 24430 | 12.02 |
03:21 ET | 18176 | 11.99 |
03:23 ET | 26999 | 11.98 |
03:25 ET | 36799 | 11.992 |
03:27 ET | 46284 | 12.03 |
03:30 ET | 17477 | 12.025 |
03:32 ET | 42443 | 12.035 |
03:34 ET | 82100 | 12.04 |
03:36 ET | 31490 | 12.03 |
03:38 ET | 41536 | 11.965 |
03:39 ET | 37424 | 11.98 |
03:41 ET | 34733 | 11.985 |
03:43 ET | 32193 | 11.995 |
03:45 ET | 35668 | 11.985 |
03:48 ET | 52069 | 11.955 |
03:50 ET | 46527 | 11.935 |
03:52 ET | 200565 | 12.02 |
03:54 ET | 153410 | 12.04 |
03:56 ET | 228697 | 12.015 |
03:57 ET | 147370 | 12.01 |
03:59 ET | 7645509 | 12 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Roivant Sciences Ltd | 8.9B | 2.2x | --- |
Corcept Therapeutics Inc | 4.1B | 37.2x | +9.80% |
Ligand Pharmaceuticals Inc | 1.9B | 46.4x | -12.71% |
Harrow Inc | 1.5B | -47.7x | --- |
Ocular Therapeutix Inc | 1.4B | -8.3x | --- |
Immunocore Holdings PLC | 1.7B | -32.2x | --- |
Roivant Sciences Ltd. is a commercial-stage biopharmaceutical company that seeks to improve the lives of patients by accelerating the development and commercialization of medicines that matter. The Company’s pipeline includes VTAMA, a novel topical approved for the treatment of psoriasis and in development for the treatment of atopic dermatitis; IMVT-1402 and batoclimab, fully human monoclonal antibodies targeting the neonatal Fc receptor (FcRn) in development across several IgG-mediated autoimmune indications; and brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 for the treatment of dermatomyositis and non-infectious uveitis, in addition to other clinical-stage molecules. It advances its pipeline by creating nimble subsidiaries or Vants to develop and commercialize its medicines and technologies. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its pipeline program also includes Mosliciguat.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $8.9B |
---|---|
Revenue (TTM) | $158.3M |
Shares Outstanding | 739.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.26 |
EPS | $5.57 |
Book Value | $7.40 |
P/E Ratio | 2.2x |
Price/Sales (TTM) | 56.3 |
Price/Cash Flow (TTM) | 1.9x |
Operating Margin | 2,799.07% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.